KALV Stock Analysis: Buy, Sell, or Hold?
KALV - KalVista Pharmaceuticals, Inc. Common Stock
$27.00
0.01 (0.04%)
▲
5d:
+0.19%
30d:
+1.09%
90d:
+48.03%
HOLD
MODERATE Confidence
Analysis Updated: Jun 10, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Smart Money Distribution
None View Scanner →
Strength: 4.6/10
Get Alerted When KALV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KALV shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KALV shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KALV is currently trading at $27.00, which is considered extended relative to its 30-day fair value range of $26.78 to $26.96.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$26.78 -
$26.96
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($28.60)
Trading Range Analysis
30-Day Trading Range
$26.78 -
$26.96
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.12
(4.1%)
Support & Resistance Levels
Support Level
$26.77
Resistance Level
$27.00
Current Trend
Strong Uptrend
Technical data as of
Jun 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.68
Wall Street Target
$28.60
(+5.9%)
Revenue Growth (YoY)
30.7%
Profit Margin
-118.7%
Share & Embed Analysis
Last updated: June 24, 2026 2:36 AM ET
Data refreshes hourly during market hours. Next update: 3:36 AM
Data refreshes hourly during market hours. Next update: 3:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KALV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Piekos
SELL
1862 shares
2026-04-17
Nicole Sweeny
SELL
1862 shares
2026-04-17
Paul K Audhya
SELL
2686 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
